09:13 AM EST - Avant Technologies Inc : Along with its JV partner, Ainnova Tech, Inc., a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence, today announced the completion of its milestone meeting with the U.S. Food and Drug Administration. The pre-submission meeting allowed Ainnova and its Contract Research Organization, Fortrea, to present and discuss Ainnova's planned clinical trial for its Vision AI platform in the early detection of diabetic retinopathy and receive critical feedback from the FDA. Ainnova's clinical trial will be conducted exclusively in the United States and focus solely on diabetic retinopathy. Avant Technologies Inc
shares O.AVAI are trading off $0.04 at $0.53.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=AVAI&qmodStoryID=7236807087101061
